Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $357.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Canaccord Genuity Group from $283.00 to $357.00 in a research report released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Evercore ISI lifted their […]
More Stories
Digital Ally (NASDAQ:DGLY) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Digital Ally (NASDAQ:DGLY – Free Report) in a research report sent to investors on...
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per...
LCI Industries (NYSE:LCII) to Issue Dividend Increase – $1.15 Per Share
LCI Industries (NYSE:LCII – Get Free Report) declared a quarterly dividend on Thursday, November 14th,RTT News reports. Shareholders of record...
CleanSpark (NASDAQ:CLSK) vs. Binah Capital Group (NASDAQ:BCG) Head-To-Head Comparison
CleanSpark (NASDAQ:CLSK – Get Free Report) and Binah Capital Group (NASDAQ:BCG – Get Free Report) are both finance companies, but...
ADVFN (LON:AFN) Shares Down 8.1% – What’s Next?
ADVFN Plc (LON:AFN – Get Free Report)’s share price dropped 8.1% during mid-day trading on Thursday . The company traded...
ICC Labs (CVE:ICC) Trading Down 5.8% – What’s Next?
ICC Labs Inc. (CVE:ICC – Get Free Report) dropped 5.8% during mid-day trading on Thursday . The stock traded as...